These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35234696)

  • 1. Therapeutic developments in metabolic dysfunction-associated fatty liver disease.
    Shi Y; Fan J
    Chin Med J (Engl); 2022 May; 135(9):1009-1018. PubMed ID: 35234696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit.
    Fabris L; Campello E; Cadamuro M; Simioni P
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166763. PubMed ID: 37951510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
    Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
    Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.
    Theofilis P; Vordoni A; Kalaitzidis RG
    World J Gastroenterol; 2022 Oct; 28(39):5691-5706. PubMed ID: 36338895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-Associated Fatty Liver Disease and Diabetes: A Double Whammy.
    Kapoor N; Kalra S
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):469-484. PubMed ID: 37495338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes.
    Mastromauro C; Polidori N; Giannini C
    Curr Opin Pediatr; 2022 Aug; 34(4):414-422. PubMed ID: 35836399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.
    Eslam M; El-Serag HB; Francque S; Sarin SK; Wei L; Bugianesi E; George J
    Nat Rev Gastroenterol Hepatol; 2022 Oct; 19(10):638-651. PubMed ID: 35710982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.
    Lim S; Kim JW; Targher G
    Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.
    Miyake T; Matsuura B; Furukawa S; Ishihara T; Yoshida O; Miyazaki M; Watanebe K; Shiomi A; Nakaguchi H; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Takeshita E; Kumagi T; Abe M; Ikeda Y; Iwata T; Hiasa Y
    J Diabetes Investig; 2022 Jul; 13(7):1245-1252. PubMed ID: 35167194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.
    Jeeyavudeen MS; Chaudhari R; Pappachan JM; Fouda S
    World J Gastroenterol; 2023 Jan; 29(3):487-502. PubMed ID: 36688018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
    Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
    Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective.
    Nardolillo M; Rescigno F; Bartiromo M; Piatto D; Guarino S; Marzuillo P; Miraglia Del Giudice E; Di Sessa A
    World J Gastroenterol; 2024 Apr; 30(15):2081-2086. PubMed ID: 38681989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bidirectional Association Between Obstructive Sleep Apnea and Metabolic-Associated Fatty Liver Disease.
    Preshy A; Brown J
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):509-520. PubMed ID: 37495341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
    Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
    Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
    Lee H; Lim TS; Kim SU; Kim HC
    Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.